An In Silico Analysis Identified FZD9 as a Potential Prognostic Biomarker in Triple-Negative Breast Cancer Patients.
Daniel Rodrigues de BastosAna Paula Picaro MichelliJean Michel Rocha Sampaio LeiteRafael André da SilvaRicardo Cesar CintraJeniffer Johana Duarte SanchezCesar Augusto Sam Tiago Vilanova-CostaAntonio Márcio Teodoro Cordeiro SilvaPublished in: European journal of breast health (2020)
Our cumulative results demonstrated that FZD9 plays an important role in TNBC and may be a potential prognostic biomarker. Nevertheless, further in vitro and in vivo assays are necessary to confirm our findings and to strengthen the evidences about the mechanisms by which FZD9 functions in these tumors.